Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by AtonRa Partners

AtonRa Partners decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% during the 4th quarter, Holdings Channel reports. The fund owned 475 shares of the medical research company’s stock after selling 45 shares during the quarter. AtonRa Partners’ holdings in Thermo Fisher Scientific were worth $252,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. WCM Investment Management LLC grew its stake in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after buying an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. increased its holdings in shares of Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after acquiring an additional 1,654 shares during the period. DMC Group LLC raised its position in Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after purchasing an additional 84 shares during the last quarter. S. R. Schill & Associates grew its position in Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after purchasing an additional 792 shares during the last quarter. Finally, Check Capital Management Inc. CA acquired a new position in Thermo Fisher Scientific in the third quarter valued at $219,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group raised their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Deutsche Bank Aktiengesellschaft increased their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $3.50 during mid-day trading on Tuesday, reaching $573.39. 267,946 shares of the company’s stock were exchanged, compared to its average volume of 1,538,784. The company has a 50-day simple moving average of $574.18 and a two-hundred day simple moving average of $531.06. The company has a market cap of $218.87 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 2.41 and a beta of 0.80. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,277 shares of company stock valued at $29,649,264. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.